What the CJC-1295 research record actually measured

CJC-1295 as a Long-Acting GHRH Analog

The CJC-1295 research record begins with its mechanism. CJC-1295 binds the GHRH receptor — a class B G-protein-coupled receptor — on anterior-pituitary somatotrophs, activating Gs/cAMP/PKA signaling that drives growth-hormone synthesis and release ^[2]. The released GH then acts on hepatic GH receptors to raise IGF-1, the downstream hormone that mediates much of GH's anabolic effect ^[2].

That two-step axis — pituitary GH up, then hepatic IGF-1 up — is what every CJC-1295 study ultimately measures. The compound does not supply growth hormone; it amplifies the body's own production by acting one rung upstream, at the receptor the hypothalamus normally uses. Because the signal originates at the pituitary rather than bypassing it, the downstream GH pulses retain much of their natural shape, a property the human studies confirmed directly ^[3].

CJC-1295 as a Long-Acting GHRH Analog

As a GHRH analog, CJC-1295 differs from native GHRH in two engineered ways. Four substitutions (D-Ala at position 2, plus changes at 8, 15 and 27) stabilize the peptide's helix and block dipeptidylpeptidase-IV cleavage, deamidation and oxidation ^[2]. In the DAC variant, a maleimidopropionyl linker performs a Michael addition onto the free thiol of circulating serum albumin, forming a covalent peptide-albumin conjugate whose half-life trends toward that of albumin itself ^[2]. In rats, this conjugate produced a 4-fold higher GH area-under-the-curve over two hours than unconjugated hGRF(1-29) and remained detectable in plasma beyond 72 hours ^[2]. A 2025 Nature Reviews Endocrinology review situates CJC-1295 within the broader GHRH-analog class alongside sermorelin and tesamorelin ^[12].

Half-Life and the Human Pharmacokinetic Studies

The defining human data come from two early studies. In healthy adults aged 21 to 61, single subcutaneous doses of 30 or 60 micrograms per kilogram produced dose-dependent 2- to 10-fold increases in mean plasma GH for six days or more and 1.5- to 3-fold increases in IGF-1 for nine to eleven days; after multiple doses, IGF-1 stayed above baseline for up to 28 days, with an estimated CJC-1295 half-life of 5.8 to 8.1 days ^[1].

Half-Life: 5.8-8.1 Days (DAC) vs Minutes-to-Hours (No-DAC)

That 5.8-to-8.1-day figure belongs to the DAC form ^[1]. The no-DAC Modified GRF (1-29), lacking the albumin handle, clears in the minutes-to-hours range, reflecting native GHRH(1-29) kinetics modified only by the protease-resistant substitutions ^[8]. Early pharmacokinetic work on synthetic GRF(1-29)NH2 established that the unmodified fragment has a short circulating half-life in healthy men, which is precisely the problem the long-acting program was built to solve ^[9]. PEGylation of GHRH analogs was explored as an alternative half-life-extension strategy, illustrating the broader medicinal-chemistry problem that albumin conjugation addressed ^[10].

What to expect when taking CJC-1295?

This is a research-context question, not a use recommendation. In human PK studies, single doses raised mean GH several-fold and IGF-1 by roughly 45%, with effects persisting for days ^[3]. Outcomes in uncontrolled, non-trial settings are not established, and no human dosing is approved for any indication.

What the Research Reports: GH and IGF-1 Responses

The most carefully characterized human finding concerns the pattern of GH release, not just its magnitude. In healthy men aged 20 to 40, a single subcutaneous dose of 60 or 90 micrograms per kilogram raised trough GH approximately 7.5-fold, mean GH by about 46% and IGF-1 by about 45% one week later — while the frequency and magnitude of pulsatile GH secretion were unaltered ^[3]. In other words, the GH axis kept its natural pulse-like rhythm even under sustained stimulation.

What the Research Reports: GH and IGF-1 Responses

That preserved pulsatility is a meaningful result, because continuous, non-pulsatile GH elevation is generally considered less physiological. A separate proteomic study in 11 healthy young men found reproducible serum protein changes after CJC-1295 — decreased apolipoprotein A1 and a transthyretin isoform, increased albumin-fragment and immunoglobulin species — with one signal correlating linearly with IGF-1, identifying candidate biomarkers of GH/IGF-1 axis activation ^[4]. In GHRH-knockout mice, 2 micrograms once every 24 hours fully normalized body weight and length, whereas dosing every 48 to 72 hours was progressively less effective, and treatment raised pituitary GH mRNA ^[6].

Does CJC-1295 and ipamorelin work?

Mechanistically, GHRH analogs and growth-hormone-releasing peptides act on different receptors, and co-administration produces GH release greater than either alone ^[11]. Controlled efficacy data for the specific CJC-1295/ipamorelin pairing in healthy adults are limited; the rationale is mechanistic, not a validated regimen.

CJC-1295 and Ipamorelin: the Two-Receptor Rationale

The widely discussed CJC-1295 ipamorelin pairing rests on a two-receptor model. CJC-1295 is a GHRH analog acting on the GHRH receptor; ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the ghrelin/GH-secretagogue receptor ^[11]. Because the two engage distinct pathways, ghrelin and GH secretagogues potentiate GHRH-induced GH release, producing a combined effect greater than the sum of either alone ^[11].

What is CJC-1295 ipamorelin?

It is a common research pairing of a GHRH analog (CJC-1295) with a selective GH secretagogue (ipamorelin); the two engage distinct pathways and synergize on GH release ^[11]. The combination is a mechanistic rationale, not a validated or recommended human regimen, and no controlled efficacy trial of the specific pairing in healthy adults is available ^[11].

How much CJC-1295 / ipamorelin should I take?

There is no controlled human trial of the CJC-1295/ipamorelin pairing from which to derive a dose. The basis for combining them is mechanistic — distinct receptors and supra-additive GH release — not a tested protocol ^[11]. Fixed-dose figures circulating in forums are not derived from controlled human research.

How CJC-1295 Sits Among GHRH Analogs (Sermorelin, Tesamorelin)

CJC-1295 belongs to the same class as sermorelin and the FDA-approved analog tesamorelin, but it is distinguished by its engineered duration. Where sermorelin (essentially native GHRH(1-29)) is short-acting, CJC-1295 DAC's albumin conjugation gives it a multi-day half-life ^[2][12]. Tesamorelin is the closest approved-drug comparator and is the legitimate clinical reference point against which off-label GHRH-analog interest is contrasted ^[12]. CJC-1295 itself reached only early human PK studies before its development was discontinued ^[7].

How to read this evidence base

Taken together, the CJC-1295 literature is internally consistent and mechanistically clear, but narrow. The pharmacokinetics are well characterized: a multi-day half-life for the DAC form, multi-day GH and IGF-1 elevation, and preserved pulsatility, each reproduced in more than one study ^[1][3]. The animal work — the 4-fold GH AUC in rats and the once-daily normalization of growth in GHRH-knockout mice — supports the same picture from the preclinical side ^[2][6].

What the record does not contain is just as important to state. There is no large, controlled efficacy trial in healthy adults, no long-term safety dataset, and no published outcome study for the popular CJC-1295/ipamorelin pairing ^[7][11]. The strongest claims that can be made are therefore about hormone kinetics, not about clinical benefit. A 45% rise in IGF-1 one week after a dose is a measured pharmacodynamic effect ^[3]; it is not, by itself, evidence of any health outcome.

The compound's analytical footprint reinforces how it actually circulates: CJC-1295 has been structurally identified by high-resolution LC-MS/MS in a seized 'GHRH' preparation, confirming both its identity and the gray-market context in which it is often encountered ^[16]. For the regulatory standing that follows from all of this, see the regulatory and anti-doping status, and for the complete sourcing, the full reference list.